AIM

Culture & Overview

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products include Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). AIM ImmunoTech continues to operate as a public company, conduct clinical research involving Ampligen in oncology and Long COVID, and manage its capital structure through offerings and financing agreements. The company has regained compliance with NYSE American’s continued listing standards related to stockholders’ equity. Recent news highlights include CEO Thomas K. Equels' article in Breaking Defense and the company's participation in the Virtual Investor “Why Now” conference. - ### Recent Events September 4, 2026 at 12:00 AM UTC 8-K: Corporate Changes & Voting Matters See Full Filing August 11, 2026 at 12:00 AM UTC 8-K: Corporate Changes & Voting Matters See Full Filing August 10, 2026 at 12:00 AM UTC 8-K: Corporate Changes & Voting Matters See Full Filing August 7, 2026 at 12:00 AM UTC 10-Q: Periodic Financial Reports See Full Filing August 6, 2026 at 12:00 AM UTC 8-K: - Based on the information provided in recent news releases and SEC filings, AIM ImmunoTech continues to operate as a public company, conduct clinical research involving Ampligen in oncology and Long COVID, and manage its capital structure through offerings and financing agreements. The company has also announced a stock dividend of one share of common stock for every 1,000 shares of outstanding com - [2:06] organizations that use, implement, resell, or develop barcoding, RFID, RTLS, and asset tracking technologies. [2:15] We've been doing this for over 50 years. [2:18] Our mission is to enable adoption, growth, and interoperability across automated data capture technologies. We [2:25] are unbiased, global, and memberdriven, representing more than 300 organizations worldwide. [...] [27:32] Comm - ## AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential AIM ImmunoTech (AIM) highlighted recent media coverage examining its investigational drug Ampligen’s potential antiviral and post-viral therapeutic applications. [...] AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels authored a new article in Breaking Defense t